A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri (Natalizumab) to Tecfidera (Dimethyl Fumarate)

Trial Profile

A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri (Natalizumab) to Tecfidera (Dimethyl Fumarate)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2015

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Natalizumab
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms STRATEGY
  • Sponsors Biogen
  • Most Recent Events

    • 28 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 22 Dec 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 22 Dec 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top